No announcement yet.

Spinal Cord Injury Articles Posted by Manouli

This is a sticky topic.
  • Filter
  • Time
  • Show
Clear All
new posts

    AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy
    Novel Technology Reactivates the Neural Tissue after Spinal Cord Injury

    May 28, 2020 10:00 AM Eastern Daylight Time
    CAMBRIDGE, Mass,--(BUSINESS WIRE)--AXONIS Therapeutics, Inc., an emerging biotechnology company advancing breakthrough research to treat spinal cord injury and paralysis, today announced the close of the first tranche of a $4 million Seed Preferred financing. The financing was led by Kerry Murphy, an investor, philanthropist and AXONIS Board member. The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity. The importance of KCC2 treatment in recovery of stepping ability was first discovered by Dr. Zhigang He in his lab at Boston Children’s Hospital.

    “We are very pleased with this seed funding, as it will allow us to initiate important pre-clinical work and build our team as we advance this technology,” said Joanna Stanicka, PhD, CEO, AXONIS Therapeutics. “We have seen very promising results in the proof-of-concept studies thus far, and look forward to moving this critical research to the next stage in our mission to treat paralysis.”


      Scientists create a drug that 'repairs damage to the brain and spinal cord' in potential breakthrough for paralysed patients and Alzheimer's sufferers
      Scientists created a synthetic version of a protein known as Cerebellin-1
      It links together brain messaging neurons, which can be lost to damage or illness
      The compound, called CPTX, repaired movement and memory function in mice
      It offers hope of new therapies for a range of devastating conditions


        Altered enzyme offers hope for spinal injury and stroke

        An enzyme proven to help regrow damaged nerve tissue in animals but too unstable for use in humans has been redesigned for stability in research co-led by Marian Hettiaratchi of the Phil and Penny Knight Campus for Accelerating Scientific Impact at the University of Oregon.

        With stability added, the enzyme found in many types of bacteria, chondroitinase ABC, could potentially be repurposed to help reverse nerve damage caused by strokes and as a treatment for spinal cord injuries.



          Simultaneous stimulation helped a spinal cord injury patient regain the ability to walk
          The simultaneous stimulation of the motor nerves of the brain and limbs (paired associative stimulation) has yielded promising research results. Research conducted at the BioMag Laboratory, operated by the University of Helsinki, Helsinki University Hospital and Aalto University, has previously demonstrated that simultaneous transcranial magnetic stimulation of the brain and electrical stimulation of the limb nerves constitute a useful method of motor rehabilitation in patients suffering from spinal cord injuries.


            Thursday, June 24, 2010
            Researchers Discover How Folate Promotes Healing In Spinal Cord Injuries
            NIH Funded Study Deciphers Chemical Sequence of Nerve Regeneration in Rats.
            AddThis Sharing Buttons
            Share to PrintShare to EmailShare to FacebookShare to TwitterShare to More
            The vitamin folate appears to promote healing in damaged rat spinal cord tissue by triggering a change in DNA, according to a laboratory study funded by the National Institutes of Health.
            The researchers showed that the healing effects of the vitamin increased with the dosage, until regrowth of the damaged tissue reached a maximum level. After this threshold was reached, regrowth declined progressively with increasing doses until it reached the level seen in the absence of the vitamin.

            Researchers Discover How Folate Promotes Healing In Spinal Cord Injuries


              Research: “Remarkable improvements” for spinal cord injury Veterans
              Aiming to implant 20 Veterans with electrodes inside the spine

              A spinal cord injury (SCI) is a debilitating medical condition. It limits the function of movement and control in the body. As a result, having an SCI can lead to reduced aerobic fitness, glucose intolerance and insulin resistance. This is due to autonomic dysfunction, muscle wasting, increased regional and total body fat mass, and relative inactivity.
              The Central Virginia VA Health Care System has unique expertise treating Veterans with these injuries.
              The Congressionally Directed Medical Research Programs has awarded a grant for $3.7 million to the Central Virginia VA Health Care System and Virginia Commonwealth University. In turn, these researchers will study spinal epidural stimulation in people with spinal cord injuries. The grant is the first of its kind at a VA medical center.
              VA research teams will collaborate on using spinal epidural stimulation treatment with a robotic suit. Hopefully, the result will be an improved quality of life for those suffering with spinal cord injuries. Researchers currently use VA’s robotic exoskeleton suits to improve SCI patients’ mobility and outlook for their prognosis.

              New Hope for People With Spinal Cord Injuries
              Sat Sep 12, 2020.
              (NAPSI)—If you or someone you care about is ever among the approximately 17,700 Americans who each year, according to The Journal of American Medical Association, suffer a new spinal cord injury or the hundreds of thousands that continue to live with a spinal cord injury, you may be relieved to learn about recent research.
              The Issue


                Science News
                from research organizations

                New smart drug delivery system may help treatment for neurological disorders
                Drug delivery technology is aimed at helping people with spinal cord and other nervous system disorders
                September 17, 2020
                Rutgers University
                A research team has created a smart drug delivery system that reduces inflammation in damaged nervous tissues and may help treat spinal cord injuries and other neurological disorders. The system, which uses extremely thin biomaterials implanted in the body, also protects nerve fibers (axons) that connect nerve cells in injured neural tissues, according to a new study.


                  Kemp Proteins Selected to Provide Assay Development for Potential First-In-Class Therapy for Chronic Spinal Cord Injury
                  Tuesday, September 22, 2020 Research News
                  // Proteins Selected to Provide Assay Development for Potential First-In-Class Therapy for Chronic Spinal Cord Injury Proteins Selected to Provide Assay Development for Potential First-In-Class Therapy for Chronic Spinal Cord


                    $13.48M Awarded To Johns Hopkins Scientists To Develop Implantable Ultrasound Devices For Patients With Spinal Cord Injury
                    12-Oct-2020 8:00 AM EDT, by Johns Hopkins Medicine
                    Newswise — A team of Johns Hopkins neurosurgeons and biomedical engineers has received $13.48 million from the Defense Advanced Research Projects Agency (DARPA) to develop implantable ultrasound and other devices that could revolutionize care for people suffering from spinal cord injuries. The results could benefit thousands of U.S. service members and civilians who sustain spinal cord injuries every year.
                    The electronic device is planned to be the size and flexibility of a small Band-Aid? and will use high-resolution ultrasound technology to help doctors monitor and treat the changes in blood flow and prevent tissue death that occur immediately after a traumatic injury to the spinal cord.
                    The research program, supported by DARPA’s Bridging the Gap (BG+) program, will draw from the clinical expertise and ingenuity of its co-leaders, Nicholas Theodore, M.D., professor of Neurosurgery and Biomedical Engineering and Amir Manbachi, Ph.D., assistant professor of Neurosurgery and Biomedical Engineering at the Johns Hopkins University School of Medicine, to bring the devices from concept to human use within an ambitious five-year timeline.